Intel stock spikes after report of possible US government stake
LONDON - Investment management firm BlackRock (NYSE:BLK), Inc. has disclosed a 1.53% stake in Mural Oncology plc, according to a regulatory filing with the Irish Takeover Panel. The position, which comprises 265,889 ordinary shares, was held as of May 30, 2025.
The disclosure was made under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022, which requires that any person with an interest in relevant securities representing 1% or more must report their position in the context of a takeover. No short positions were reported by BlackRock in the filing.
Additionally, the filing included a reference to a stock on loan transaction involving 17,800 ordinary shares of Mural Oncology. No further details were provided regarding this transaction.
BlackRock’s disclosure does not indicate any dealings in cash-settled derivatives or stock-settled derivatives related to Mural Oncology’s securities. The filing also stated that there are no indemnity or option arrangements, or any agreements or understandings relating to the voting rights of any relevant securities under any option that could be an inducement to deal or refrain from dealing.
This information, based on a press release statement, is significant for investors and the market as it reflects BlackRock’s investment position in Mural Oncology. The disclosure is a routine compliance measure and does not necessarily suggest any further action by BlackRock regarding Mural Oncology.
Mural Oncology plc has not commented on the disclosure, and the filing did not indicate any intent by BlackRock regarding its stake in the company.
The news service of the London Stock Exchange (LON:LSEG), RNS, provided this information. BlackRock’s contact for the disclosure was listed as Jana Blumenstein, with a contact number for additional inquiries.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.